Boltz Raises $110 Million Series A Led by Bessemer for AI Models That Design Drug Molecules; the Company Does Not State a Valuation

Boltz, a company that sells AI models for drug discovery, announced a $110 million Series A led by Bessemer Venture Partners on 18 November 2026, according to the company and SiliconANGLE. The company does not state a valuation. It says molecular token usage among paying customers “has grown 50-fold since June” and that it has partnerships with six of the world’s 20 largest pharmaceutical companies; those figures are the company’s own.
The round
- Lead. Bessemer; the company welcomes Andrew Hedin and Byron Deeter “as they join us.”
- Existing investors. Andreessen Horowitz, Amplify Partners, Zetta Venture Partners and Obvious Ventures, who “doubled down,” the company says.
- New investors. Greycroft, F-Prime Capital, Hummingbird and Benchling, “alongside other new amazing investors.”
- Use of funds. More compute and data, meeting partner demand and expanding the team.
What the company sells
Boltz’s first proprietary models, BoltzMol-1, for small-molecule binding and hit finding, and BoltzProt-1, for protein design, were released in June, and its Boltz Lab, launched in January, gives scientists and AI agents access to its models. SiliconANGLE says the models are sold through an interface billed by token usage. The company names Pfizer, GSK, Takeda and BMS among its partners, and says its platform serves pharmaceutical, biotech and industrial companies. It says it started in 2025 as a small group of MIT researchers and has about 40 people.
Company-reported results
Not independently verified: the company says thousands of scientists signed up within weeks of Boltz Lab’s launch and that its models found small-molecule hits and designed protein binders for “a majority of the challenging targets we pursued.” SiliconANGLE reports the company’s statement that BoltzMol-1 found hits for six of 10 targets and that unreleased models show “substantial improvements.”
Where reports differ
- Hit rate. The company’s post says “a majority” of challenging targets; SiliconANGLE gives six of 10.
- Headquarters. The company’s post does not state one; aggregator pages describe Boltz as London-based or as a US company.
- Origin. The “MIT researchers” detail is on the company’s page but not in SiliconANGLE’s article.
Sources and notes
Lens read Boltz’s announcement and SiliconANGLE, 19 November 2026 (by Maria Deutscher) through automated page summaries. Endpoints News returned a 403 error. Neither page quotes a named executive or investor.
Image: an illustration of an alpha helix, a protein structure, used as a stand-in. Illustration by explorebiology, CC BY 4.0, via Wikimedia Commons.

